Syndax grants 213,300 options: 10 analysts rate Syndax Pharmaceuticals stock Buy

Published on 10/06/2026 at 15:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Syndax awarded 213,300 options on October 1, 2026. Syndax Pharmaceuticals stock trades EUR 15.94 on October 6, 2026 after EUR 15.89, plus 0.31 percent.

SNDX, US87164F1057, Illustration mit AI erstellt.

Syndax Pharmaceuticals (ISIN US87164F1057) was trading at EUR 15.94 at Lang & Schwarz on October 6, 2026 at 3:02 p.m. CEST, while a recent company release disclosed 213,300 inducement options for nine new employees. Yahoo Finance reported on October 2, 2026 that the awards were granted on October 1. A separate MarketBeat overview listed 10 Buy ratings and one Sell rating for the stock.

Employee awards add a measured signal

The inducement plan is designed to recruit staff without an immediate cash payment. The options vest over four years, with 25 percent vesting after one year and the remaining awards vesting monthly over the following 36 months, according to Yahoo Finance.

That structure supports hiring while also adding potential dilution for existing shareholders. The award covers 213,300 shares, a concrete figure that investors can compare with future share counts and operating progress.

Revenue growth meets a sharper earnings test

Syndax reported USD 72.8 million of revenue in the second quarter of 2026, up 92 percent from the same quarter a year earlier. The company recorded a diluted loss of USD 0.55 per share and net income of minus USD 49.4 million for that period, according to the company investor-relations page.

The revenue increase is substantial, but the earnings comparison remains difficult. Syndax Pharmaceuticals reported second-quarter 2026 revenue of USD 72.8 million, compared with a USD 79.4 million analyst estimate cited by MarketBeat.

Analysts keep a wide valuation gap

H.C. Wainwright reiterated a Buy rating and a USD 38.00 price target on October 1, 2026, according to Investing.com. MarketBeat cited a broader average target of USD 41.80, alongside 10 Buy ratings and one Sell rating, in its October 2, 2026 report.

The contrast is clear: commercial revenue is expanding, yet the second-quarter loss and missed revenue estimate leave execution as the central issue. The next report is scheduled for November 2, 2026, with consensus revenue of USD 82.41 million and consensus earnings per share of minus USD 0.48, according to MarketBeat.

SNDX remains inside its yearly range

On Nasdaq, SNDX was last at USD 17.83 on October 5, 2026 at 4:00 p.m. ET. The 52-week range was USD 12.99 to USD 25.59, and market capitalization was USD 1.6 billion as of October 5, 2026.

At Lang & Schwarz, the stock was trading at EUR 15.94 on October 6, 2026 at 3:02 p.m. CEST, plus 0.31 percent versus the Lang & Schwarz prior close of EUR 15.89 on October 5, 2026.